Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Progressive has reported for 3 months of 2023

4/13/23 PGR

Novatek patents large-scale liquefaction of natural gas

4/13/23 NVTK

Rostelecom to launch production of new generation surveillance cameras and routers

4/13/23 RTKM

VKontakte has adapted chatbots to meet the needs of different business areas

4/13/23 VKCO

Delta Air Lines loss decreased by 2.6 times in Q1

4/13/23 DAL

Shareholders of Tattelecom approved dividends for 2022

4/13/23 TTLK

Commodity output by Acron Group in Q1 increased 0.6%

4/13/23 AKRN

Economic effect of VTB's digital transformation was about ₽300 billion

4/13/23 VTBR

TCS Group created a leasing company

4/13/23 T

Yandex will launch food delivery in Moscow and St. Petersburg under the brand name Market 15

4/13/23 YNDX